{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:21:44Z","timestamp":1770132104951,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/ki.2012.227","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T12:51:01Z","timestamp":1339591861000},"page":"903-908","source":"Crossref","is-referenced-by-count":42,"title":["Oral bisphosphonate use in the elderly is not associated with acute kidney injury"],"prefix":"10.1016","volume":"82","author":[{"given":"Andrew W.Y.","family":"Shih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin K.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad M.","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Hird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Hodsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2012.227_bb0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3949\/ccjm.75a.08014","article-title":"Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk?","volume":"75","author":"Carey","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1038\/ki.2012.227_bb0015","series-title":"Cochrane Database Syst Rev","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008"},{"key":"10.1038\/ki.2012.227_bb0020","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1038\/ki.2012.227_bb0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1038\/ki.2012.227_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1038\/ki.2012.227_bb0035","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1038\/ki.2012.227_bb0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1096\/fasebj.13.3.523","article-title":"Altered gene expression and functions of mitochondria in human nephrotic syndrome","volume":"13","author":"Holthofer","year":"1999","journal-title":"FASEB J"},{"key":"10.1038\/ki.2012.227_bb0045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1523-1755.2001.0590041236.x","article-title":"Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation","volume":"59","author":"Hotta","year":"2001","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.227_bb0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","article-title":"Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?","volume":"47","author":"Sauter","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2012.227_bb0055","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.227_bb0060","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1038\/ki.2012.227_bb0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1038\/ki.2012.227_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1681\/ASN.V10151","article-title":"The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy","volume":"10","author":"Barisoni","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.227_bb0075","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1038\/ki.2012.227_bb0080","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/ki.2012.227_bb0085","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.227_bb0090","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2012.227_bb0095","author":"FDA Drug Safety Communication"},{"issue":"Suppl 3","key":"10.1038\/ki.2012.227_bb0100","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF01623002","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2012.227_bb0105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00198-007-0361-9","article-title":"Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate","volume":"18","author":"Pascual","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2012.227_bb0110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1081\/JDI-65397","article-title":"Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium","volume":"27","author":"Pena de la Vega","year":"2005","journal-title":"Ren Fail"},{"key":"10.1038\/ki.2012.227_bb0115","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/ndt\/12.12.2797","article-title":"Acute renal failure and alendronate","volume":"12","author":"Zazgornik","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.227_bb0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1038\/ki.2012.227_bb0125","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2012.227_bb0130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00198-010-1359-2","article-title":"Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study","volume":"22","author":"Fraser","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2012.227_bb0135","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"10.1038\/ki.2012.227_bb0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08860220701260776","article-title":"The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women","volume":"29","author":"Yanik","year":"2007","journal-title":"Ren Fail"},{"key":"10.1038\/ki.2012.227_bb0145","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1681\/ASN.2006010073","article-title":"Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure","volume":"17","author":"Waikar","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.227_bb0150","series-title":"Canadian institute for health information discharge abstract database: a Validation Study","author":"Juurlink","year":"2006"},{"key":"10.1038\/ki.2012.227_bb0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.2008.107","article-title":"The risk of acute renal failure in patients with chronic kidney disease","volume":"74","author":"Hsu","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.227_bb0160","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1681\/ASN.2006070756","article-title":"Incidence and outcomes in acute kidney injury: a comprehensive population-based study","volume":"18","author":"Ali","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.227_bb0165","author":"Statistics Canada C"},{"key":"10.1038\/ki.2012.227_bb0170","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"10.1038\/ki.2012.227_bb0175","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJM199910283411806","article-title":"Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2012.227_bb0180","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1001\/jama.289.24.3241","article-title":"Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study","volume":"289","author":"Austin","year":"2003","journal-title":"JAMA"},{"key":"10.1038\/ki.2012.227_bb0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","article-title":"Drug-drug interactions among elderly patients hospitalized for drug toxicity","volume":"289","author":"Juurlink","year":"2003","journal-title":"JAMA"},{"key":"10.1038\/ki.2012.227_bb0190","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1532-5415.2006.00758.x","article-title":"Persistence with bisphosphonate therapy in older people","volume":"54","author":"Melo","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1038\/ki.2012.227_bb0195","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"10.1038\/ki.2012.227_bb0200","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1038\/ki.2012.227_bb0205","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.ki.5002743","article-title":"The RIFLE criteria and mortality in acute kidney injury: a systematic review","volume":"73","author":"Ricci","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.227_bb0210","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.227_bb0215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2012.227_bb0220","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Comm Stat Simulation Computation"},{"key":"10.1038\/ki.2012.227_bb0225","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"key":"10.1038\/ki.2012.227_bb0230","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1681\/ASN.2004080697","article-title":"Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance","volume":"16","author":"Garg","year":"2005","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815556500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815556500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T15:38:58Z","timestamp":1656171538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815556500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0085253815556500"],"URL":"https:\/\/doi.org\/10.1038\/ki.2012.227","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}